Extended Half-Life (EHL) Recombinant Factor IX
Treatment for Hemophilia
Typical Dosage: Prophylaxis: 50-100 IU/kg once weekly or every 10-14 days; On-demand: 10-60 IU/kg
Effectiveness
90%
Safety Score
68%
Clinical Trials
40
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Prophylaxis: 50-100 IU/kg once weekly or every 10-14 days; On-demand: 10-60 IU/kg
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
70(Treat 70 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$380,000
Monitoring:$5,000
Side Effect Mgmt:$5,000
Total Annual:$390,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$100,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$410,526.32
Comparison vs Standard Half-Life Recombinant Factor IX
Cost Difference
+$80,000/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Extended Half-Life (EHL) Recombinant Factor IX Outcomes
for Hemophilia
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Inhibitor development
+2%
Allergic reactions
+0.5%
Injection site reactions
+3%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov